Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
AstraZeneca
Johnson and Johnson
Moodys
Baxter

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR VONVENDI


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for VONVENDI

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02606045 ↗ Minimize Menorrhagia in Women With Von Willebrand Disease Recruiting Carnegie Mellon University Phase 3 2019-02-07 This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda┬«) to minimize menorrhagia in women with von Willebrand disease (VWD). The purpose of this Phase III multicenter prospective, randomized, crossover arm trial is to compare recombinant von Willebrand factor (rVWF) to tranexamic acid (TA) in reducing the severity of menorrhagia in women with von Willebrand disease.
NCT02606045 ↗ Minimize Menorrhagia in Women With Von Willebrand Disease Recruiting Duke University Phase 3 2019-02-07 This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda┬«) to minimize menorrhagia in women with von Willebrand disease (VWD). The purpose of this Phase III multicenter prospective, randomized, crossover arm trial is to compare recombinant von Willebrand factor (rVWF) to tranexamic acid (TA) in reducing the severity of menorrhagia in women with von Willebrand disease.
NCT02606045 ↗ Minimize Menorrhagia in Women With Von Willebrand Disease Recruiting University of North Carolina Phase 3 2019-02-07 This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda┬«) to minimize menorrhagia in women with von Willebrand disease (VWD). The purpose of this Phase III multicenter prospective, randomized, crossover arm trial is to compare recombinant von Willebrand factor (rVWF) to tranexamic acid (TA) in reducing the severity of menorrhagia in women with von Willebrand disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for VONVENDI

Condition Name

Condition Name for VONVENDI
Intervention Trials
Von Willebrand Diseases 2
Postpartum Hemorrhage 1
Type 1 Von Willebrand Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for VONVENDI
Intervention Trials
Von Willebrand Diseases 2
Hemorrhage 1
Von Willebrand Disease, Type 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for VONVENDI

Trials by Country

Trials by Country for VONVENDI
Location Trials
United States 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for VONVENDI
Location Trials
Pennsylvania 2
California 1
Arizona 1
Wisconsin 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for VONVENDI

Clinical Trial Phase

Clinical Trial Phase for VONVENDI
Clinical Trial Phase Trials
Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for VONVENDI
Clinical Trial Phase Trials
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VONVENDI

Sponsor Name

Sponsor Name for VONVENDI
Sponsor Trials
Margaret Ragni 2
Carnegie Mellon University 1
Duke University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for VONVENDI
Sponsor Trials
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
AstraZeneca
Harvard Business School
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.